PITTSBURGH (AP) — Mylan Inc. has received tentative FDA approval for a generic version of Bristol-Myers Squibb Co.’s
HIV drug Reyataz.

Mylan received approval under the President’s Emergency Plan for AIDS Relief.
The generic drug will be eligible for sales outside the U.S.

Reyataz, or atazanavir sulfate capsules, are used in combination with other
medications to control HIV infection.